Shots:

• The P-III IMvigor010 study involves assessing Tecentriq as an adjuvant monothx. compared to observation in 809 patients with MIUC who are at high risk for recurrence following resection
• The P-III IMvigor010 study results: did not meet its 1EPs of DFS; safety profile is consistent with the previous profiles as no new signals were identified
•  Tecentriq is mAb targeting PD-L1 which is expressed on tumor cells and tumor-infiltrating immune cells- blocking its interactions with both PD-1 and B7.1 receptor- currently being evaluated in P-III studies for early & advanced BC and in P-II studies for multiple cancer indications

Click here ­to­ read full press release/ article 

Ref: GlobeNewswire  | Image: Roche